| Code | CSB-RA007918MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of REGN9533, targeting coagulation factor XII (F12; FXII)—the zymogen that initiates the plasma contact system. Upon activation to FXIIa, FXII can drive thrombus formation primarily through the FXI-mediated intrinsic coagulation pathway, and it also links coagulation to inflammation via activation of the kallikrein–kinin system (bradykinin generation). Notably, inherited FXII deficiency is classically not associated with a bleeding phenotype, which has motivated FXII as a potential “lower-bleeding-risk” antithrombotic target for mechanistic exploration.
REGN9533 is being evaluated clinically as a monoclonal antibody against Factor XII, including a Phase 1 study in healthy adults assessing safety, PK and PD. This biosimilar enables researchers to investigate FXII biology and contact-pathway pharmacology—including target engagement, FXII/FXIIa-driven coagulation amplification, and inflammation-linked readouts—independent of small-molecule confounders. It supports assay development and translational workflows aimed at dissecting how FXII inhibition may modulate thrombosis-relevant pathways while minimizing impacts on physiological hemostasis.
There are currently no reviews for this product.